
[Reporter’s Notebook] Is NeuroBiogen’s tisolagiline really worth $4.5 billion?
NeuroBiogen's Wednesday announcement of a 6.5 trillion won ($4.55 billion) licensing deal with U.S.-based Scilex Bio for its experimental oral drug tisolagiline has certainly grabbed headlines in the Korean media. The drug, targeting both obesity and …